Study Published in Peer-Reviewed Journal Shows MiSight® 1 day Provides Desirable Myopic Defocus for Higher Prescriptions

A newly published study in a peer-reviewed journal reinforces prescribing confidence in CooperVision’s MiSight® 1 day soft contact lenses for higher prescriptions, demonstrating their ability to deliver consistent retinal defocus in more prolate-shaped eyes commonly associated with higher myopia. The performance is consistent with the optical profile that has been shown to slow myopia progression in powers to correct low and moderate levels of myopia.* 1

Recently published in Ophthalmic and Physiological Optics, the research journal of the UK's College of Optometrists, Accommodative Behavior and Retinal Defocus in Highly Myopic Eyes Fitted with a Dual Focus Myopia Control Contact Lens (Meyer D et al.) is now accessible via Open Access.

“This study provides compelling evidence that MiSight® 1 day delivers consistent defocus from the treatment zones across a wide range of myopia levels,” said Paul Chamberlain, Senior Director of Research Programs at CooperVision and one of the paper’s authors. “The research marks the latest data in a years-long collaboration to overcome instrumentation limitations and develop a precise, advanced technique for measuring treatment impact.”

Investigators evaluated teenagers and young adults who had high myopia (−6.50 to −9.25 D).† They found that accommodative behavior remained stable fitted with single vision and dual focus lenses. This is particularly relevant as higher levels of myopia are often associated with larger accommodative lags.

Additionally, the work illustrated that MiSight® 1 day achieved significant optical defocus across varying viewing distances and retinal regions. Measured retinal defocus within the annular treatment zone was approximately −2.00 D at the foveal center, 10° nasal and temporal and 20° nasal and reduced to −1.90 (0.57) D at 20° temporal. This consistent level of myopic defocus helps ensure effective optical signaling, which is key to slowing myopia progression in wearers.

These findings strengthen the evidence for MiSight® 1 day in myopia management for higher prescriptions, offering eye care professionals valuable data to guide clinical decisions and contributing to the expanding research on optical interventions for myopia control. For more information on CooperVision’s myopia control and management advancements, visit www.coopervision.com.